Biosynex acquires Avalun to become European leader in rapid diagnostic testing
Biosynex signed a binding offer to acquire 100% of the stock in Avalun SAS, a company developing the Labpad in vitro diagnostic device that provides rapid biological test results from [...]
Biosynex announces that it has signed a binding offer to acquire 100% shares of the Avalun
BIOSYNEX, which has established itself with the COVID-19 pandemic as a key player in decentralized biology, is highly complementary to AVALUN. Read more
ICASA 2019 : Inside the Community Village
BIOSYNEX was highlighted at ICASA 2019 in the context of the « community village », a platform for exchanges and listening between key populations and actors in the fight against [...]
Excerpt from German TV news, national channel ARD, week of 23 July 2018
As the HIV Conference begins in Amsterdam and brings together policy makers, the pharmaceutical industry and many associations from around the world, the TV report shows an increase in the [...]
Selftesting : the global challenge
Biosynex has the great pleasure to invite you to a conference focusing on selftesting and new rapid test developments (multiplexing).
MEDICA trade fair (November 12-15th, 2018) – Düsseldorf, GERMANY
Come and meet the Biosynex team booth n°3E42 at MEDICA trade fair in Düsseldorf.
